Skip to Content

Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference

RICHMOND, VA., July 9 /CNW/ - Insmed Inc. (NASDAQ:INSM), a  biopharmaceutical company focused on the development and approval of drugs for  the treatment of metabolic diseases with unmet medical needs, today announced  that it will present at this week's C.E. Unterberg, Towbin (CEUT) Emerging Growth Opportunities Conference in New York City.   

The conference, to be held at the Mandarin Oriental Hotel in New York  City, will run from Tuesday, July 10th through Thursday, July 12th. Dr.  Geoffrey Allan, Ph.D., Insmed's President and CEO, will make the presentation  on Thursday, July 12th at 8:30 a.m.; the Company will also hold one-on-one  meetings with investment firm representatives. A live video Webcast of the  presentation will be available at the investor relations section of Insmed's  website,   

Dr. Allan said, "We are especially pleased to be participating in this  year's CEUT conference, because it gives us an ideal forum to present our dual  strategy growth plan, based on our approved proprietary protein platform and  the development and manufacture of follow-on biologics, to a crucial audience  of investment managers and analysts. Insmed has a very timely story to tell,  and we are glad to get this opportunity to tell it at such a high-visibility  event."   

About Insmed   

Insmed is a biopharmaceutical company focused on the development and  approval of drugs for the treatment of metabolic diseases with unmet medical  needs. For more information please visit   

Forward Looking Statements: This release contains forward-looking  statements which are made pursuant to provisions of Section 21E of the  Securities Exchange Act of 1934. Investors are cautioned that such statements  in this release, including statements relating to planned clinical study  design, regulatory and business strategies, plans and objectives of management  and growth opportunities for existing or proposed products, constitute  forward-looking statements which involve risks and uncertainties that could  cause actual results to differ materially from those anticipated by the  forward-looking statements. The risks and uncertainties include, without  limitation, risks that product candidates may fail in the clinic or may not be  successfully marketed or manufactured, the Company may lack financial  resources to complete development of product candidates, the FDA may interpret  the results of studies differently than the Company, competing products may be  more successful, demand for new pharmaceutical products may decrease, the  biopharmaceutical industry may experience negative market trends and other  risks and challenges detailed in the Company's filings with the U.S.  Securities and Exchange Commission, including the Company's Quarterly Report  on Form 10-Q for the quarter ended March 31, 2007. Readers are cautioned not  to place undue reliance on any forward-looking statements which speak only as  of the date of this release. The Company undertakes no obligation to publicly  release the results of any revisions to these forward-looking statements that  may be made to reflect events or circumstances that occur after the date of  this release or to reflect the occurrence of unanticipated events.   

Posted: July 2007